（文章来源：证券日报） 证券日报网讯 10月20日晚间，华润双鹤发布公告称，近日，公司全资子公司北京万辉双鹤药业有限责 任公司收到了国家药品监督管理局颁发的阿法骨化醇软胶囊《药品注册证书》。 ...

阿法骨化醇软胶囊适用于治疗内源性1,25-二羟基维生素D3产生不足所致的钙代谢紊乱性疾病。例如肾 性骨营养不良、术后性或特发性甲状旁腺功能低下症、假性甲状旁腺功能低下症、作为第三性甲状旁腺 功能亢进的辅助治疗、抗维生素D性佝偻病或骨软化症、维生素D依赖型佝偻病、新生儿低钙血症或佝 偻病、钙吸收不良症、骨质疏松症、吸收不良性及营养性佝偻病及骨软化症。 格隆汇10月20日丨华润双鹤(600062.SH)公布，公司全资子公司北京万辉双鹤药业有限责任公司(称"万辉 双鹤")收到了国家药品监督管理局颁发的阿法骨化醇软胶囊(简称"该药品")《药品注册证书》。 ...

华润双鹤（600062）(600062.SH)发布公告，近日，公司全资子公司北京万辉双鹤药业有限责任公司(简 称"万辉双鹤")收到了国家药品监督管理局颁发的阿法骨化醇软胶囊《药品注册证书》。 阿法骨化醇软胶囊适用于治疗内源性1,25-二羟基维生素D3产生不足所致的钙代谢紊乱性疾病。例如肾 性骨营养不良、术后性或特发性甲状旁腺功能低下症、假性甲状旁腺功能低下症、作为第三性甲状旁腺 功能亢进的辅助治疗、抗维生素D性佝偻病或骨软化症、维生素D依赖型佝偻病、新生儿低钙血症或佝 偻病、钙吸收不良症、骨质疏松症、吸收不良性及营养性佝偻病及骨软化症。 ...

阿法骨化醇软胶囊适用于治疗内源性1,25-二羟基维生素D3产生不足所致的钙代谢紊乱性疾病。例如肾 性骨营养不良、术后性或特发性甲状旁腺功能低下症、假性甲状旁腺功能低下症、作为第三性甲状旁腺 功能亢进的辅助治疗、抗维生素D性佝偻病或骨软化症、维生素D依赖型佝偻病、新生儿低钙血症或佝 偻病、钙吸收不良症、骨质疏松症、吸收不良性及营养性佝偻病及骨软化症。 智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司全资子公司北京万辉双鹤药业有限责任 公司(简称"万辉双鹤")收到了国家药品监督管理局颁发的阿法骨化醇软胶囊《药品注册证书》。 ...

华润双鹤公告，全资子公司北京万辉双鹤药业有限责任公司收到国家药品监督管理局颁发的阿法骨化醇 软胶囊《药品注册证书》。该药品适用于治疗内源性125-二羟基维生素D3产生不足所致的钙代谢紊乱 性疾病，如肾性骨营养不良、术后性或特发性甲状旁腺功能低下症、假性甲状旁腺功能低下症、作为第 三性甲状旁腺功能亢进的辅助治疗、抗维生素D性佝偻病或骨软化症、维生素D依赖型佝偻病、新生儿 低钙血症或佝偻病、钙吸收不良症、骨质疏松症、吸收不良性及营养性佝偻病及骨软化症。公司于2022 年8月启动该药品的仿制药研发工作，于2024年6月18日提交上市许可申请，于2024年6月25日获得受理 通知书，并于2025年10月14日获得批准上市。截至公告日，公司累计研发投入为493.02万元人民币。 ...

Core Viewpoint - Kunming Pharmaceutical Group's stock price has experienced significant volatility, with a sharp decline following a brief rise, raising concerns among investors regarding its performance and future growth plans [2][3]. Financial Performance - In 2024, Kunming Pharmaceutical Group reported revenue of 8.401 billion yuan, a slight decrease of 0.34% year-on-year, while net profit attributable to shareholders increased by 19.86% to 648 million yuan [3]. - However, in Q1 2025, the company faced a substantial decline in performance, with revenue dropping by 16.53% to 1.608 billion yuan and net profit falling by 31.06% to approximately 90.48 million yuan [3][7]. - The company aims for double-digit revenue growth in 2025, despite the challenges faced in the first quarter [5][7]. Strategic Transition - The company is undergoing a significant transformation in its sales and channel management, moving from a decentralized distribution model to a more integrated and structured approach [4][5]. - The new channel system aims to enhance brand recognition and operational efficiency, focusing on long-term brand building and better collaboration with distributors [5][7]. Market Focus - Kunming Pharmaceutical Group is targeting the aging population and chronic disease management, positioning itself as a leader in the "silver health industry" [7][8]. - The company’s product portfolio includes treatments for cardiovascular diseases, with a noted decline in revenue from this segment, which fell by 17.45% to 2.195 billion yuan in 2024 [8]. Product Performance - Sales of key products, such as the blood stasis series and Tianma injection, have shown mixed results, with significant declines in some areas, such as a 54.66% drop in sales volume for the freeze-dried blood stasis injection [9]. - The company is actively working to improve its market presence and sales channels, particularly in retail and smaller medical institutions [9].